Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -. Biogen also updated its FY24 guidance to $15.00-16.00 EPS. Biogen […]
Biogen (NASDAQ:BIIB – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $15.00-16.00 for the period, compared to the consensus earnings per share estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue estimate of $9.47 billion. […]
Biogen (NASDAQ:BIIB – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $15.00-16.00 for the period, compared to the consensus earnings per share estimate of $15.49. The company issued revenue guidance of decline low- to mid-single digits, compared to the consensus revenue […]
Harvest Fund Management Co. Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,290 shares of the biotechnology company’s stock after purchasing an additional 133 shares during the […]
Biogen (NASDAQ:BIIB – Free Report) had its price objective reduced by Wedbush from $245.00 to $213.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Wedbush also issued estimates for Biogen’s Q1 2024 earnings at $3.25 EPS, Q3 2024 earnings at $4.13 EPS, […]